Spain's Almirall sees downturn in 3rd-qtr 2010 sales and incomes, but in line with guidance
Spain's largest drugmaker Almirall (ALM: SM) said that third quarter 2010 net sales were slightly eroded (-3.5%) to 676.5 millillion euros ($926.8 million) with steady growth of the international affiliates (+1.9%) and lower performance from the domestic business (-4.6%) and partners (-9.1%). International sales accounted for 43% of the total.
Net income and normalized net income totalled 121.0 million euros (-14.0%) and 121.9 million euros (-4.0%), respectively. The former was largely driven by the divestment of 13 products in first-quarter 2009 (which provided a non-recurrent item), whereas the latter is well aligned with guidance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze